Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Fylnetra Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Single-dose prefilled syringe—1 (w. needle)
Manufacturer
Mechanism of Action
Pegfilgrastim is a colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Fylnetra Indications
Indications
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
Limitations of Use
Not for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Fylnetra Dosage and Administration
Adults and Children
See full labeling. Do not give between 14 days before and 24 hours after chemotherapy. ≥45kg: 6mg SC once per chemotherapy cycle. Children (<10kg): 0.1mg/kg; (10–20kg): 1.5mg; (21–30kg): 2.5mg; (31–44kg): 4mg. Direct administration of prefilled syringe with doses <6mg is not recommended.
Fylnetra Contraindications
Not Applicable
Fylnetra Boxed Warnings
Not Applicable
Fylnetra Warnings/Precautions
Warnings/Precautions
Monitor for splenomegaly, splenic rupture, acute respiratory distress syndrome (ARDS); evaluate if fever, lung infiltrates, or respiratory distress occurs; discontinue if ARDS diagnosed. Permanently discontinue if serious allergic reactions develop. Sickle cell disorders; discontinue if sickle cell crisis occurs. Monitor for glomerulonephritis; consider dose reduction or interruption if treatment-related. Monitor CBCs, platelet counts during therapy. Discontinue if aortitis is suspected. Myeloid malignancies. Myelodysplasia. Monitor for MDS/AML in those with breast or lung cancer. Possible transient (+) bone imaging changes in nuclear imaging. Pregnancy. Nursing mothers.
Fylnetra Pharmacokinetics
Elimination
Half-life: 15–80 hours.
Fylnetra Interactions
Not Applicable
Fylnetra Adverse Reactions
Adverse Reactions
Bone or extremity pain; anaphylaxis, ARDS, splenic rupture, glomerulonephritis, leukocytosis, aortitis, thrombocytopenia, capillary leak syndrome (monitor closely if occurs).
Fylnetra Clinical Trials
See Literature
Fylnetra Note
Not Applicable
Fylnetra Patient Counseling
See Literature
Images
